Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | G6PD | P11413 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25131711 | 0.78 | TDP1 (0.47) | TDP1MAPTGAANPC1ALDH1A1 | |
| SCHEMBL29284057 | 0.77 | TDP1 (0.42) | TDP1ALDH1A1POLBTSHRL3MBTL1 | |
| SCHEMBL29206809 | 0.77 | ALDH1A1 (0.39) | TDP1MAPTGAANPC1ALDH1A1 | |
| SCHEMBL29770615 | 0.76 | ALDH1A1 (0.38) | TDP1ALDH1A1CYP1A2CYP2C19LMNA | |
| SCHEMBL15577470 | 0.76 | ALDH1A1 (0.38) | TDP1MAPTGAANPC1ALDH1A1 | |
| SCHEMBL16387120 | 0.76 | ALDH1A1 (0.38) | TDP1ALDH1A1CYP1A2CYP2C19LMNA | |
| SCHEMBL15941543 | 0.76 | MAPT (0.43) | TDP1MAPTCASP1GAANPC1 | |
| SCHEMBL13351317 | 0.76 | MAPT (0.39) | TDP1MAPTCASP1GAANPC1 | |
| SCHEMBL1750877 | 0.74 | ALDH1A1 (0.37) | TDP1ALDH1A1CYP1A2CYP2C19LMNA | |
| SCHEMBL27238766 | 0.74 | ALDH1A1 (0.37) | TDP1MAPTALDH1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276977-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2025-09-04 | — | — | US | disclosed |
| US-12312339-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025090809-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-119161346-A | Pyrrolo-ring compound and application thereof in medicine | 康百达（四川）生物医药科技有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-113811534-B | TYK2 inhibitors and uses thereof | 阿鲁米斯公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| CN-118005615-A | Pyridazine compound and preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2024-05-10 | — | — | CN | disclosed |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-117794529-A | POLO-like kinase 4 inhibitors | 欧瑞克制药公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4337198-A1 | POLO LIKE KINASE 4 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2004108707-A1 | PYRIDAZINIL QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| EP-0948495-B1 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | AMGEN INC (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6605634-B2 | Tumor necrosis factor alpha and interleukin-1 (IL-1) mediated diseases; pain, diabetes; cyclooxygenase inhibition | AMGEN, INC. | 2003-08-12 | — | — | US | disclosed |
| US-20030096819-A1 | Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents | AMGEN INC. | 2003-05-22 | — | — | US | disclosed |
| US-6440973-B1 | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents | AMGEN INC. | 2002-08-27 | — | — | US | disclosed |
| US-6180643-B1 | ANTAGONIST OF INTERLEUKINS, TUMOR NECROSIS FACTOR | AMGEN INC. | 2001-01-30 | — | — | US | disclosed |
| EP-0948495-A1 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | Amgen Inc., (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998022457-A9 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022457-A1 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | AMGEN INC. (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276977-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | TDP1 252/4885MAPT 669/4885CASP1 1831/4885 |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | TDP1 659/4885MAPT 1102/4885CASP1 3608/4885 |
| US-20030096819-A1 | Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents | TNF, IL1A, IL6 | TDP1 1813/4885MAPT 4243/4885CASP1 120/4885 |
| US-12312339-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | TDP1 659/4885MAPT 1102/4885CASP1 3608/4885 |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | TDP1 649/4885MAPT 1151/4885CASP1 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.